grey arrow to go to previous Omnicell webpage or forward to next Omnicell pageBack to Press Release

July 21, 2020

Omnicell to Release Second Quarter 2020 Earnings Results on July 28, 2020

Download PDF

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Jul. 21, 2020-- Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will hold a conference call on Tuesday, July 28, 2020, to discuss the Company’s Second Quarter 2020 financial results.


Omnicell Second Quarter 2020 earnings conference call and webcast


July 28, 2020, 1:30 p.m. PT


Randall Lipps, chairman, president, chief executive officer, and founder Peter Kuipers, chief financial officer


The conference call can be monitored by dialing 1-800-696-5518 within the U.S. or 1-706-758-4883 for all other locations. The Conference ID # is 2686514.
The webcast can be accessed at:


Available starting at 5:00 p.m. PT on July 28, 2020, through 11:59 p.m. PT on August 29, 2020. Dial 1-855-859-2056 within the U.S. and 1-404-537-3406 for all other locations, Conference ID # 2686514

About Omnicell

Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and expert services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 6,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 40,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. To learn more, visit*

*From time to time, Omnicell may use the Company’s investor relations site and other online and social media channels, including our Twitter, LinkedIn, and Facebook, to disclose material non-public information and comply with our disclosure obligations under Regulation Fair Disclosure (“FD”).


Peter Kuipers
Omnicell, Inc.
(650) 251-6100

Source: Omnicell, Inc.